Biogen (BIIB) Net Cash Flow (2009 - 2026)
Biogen (BIIB) posted quarterly Net Cash Flow of -$2.1 billion for Q2 2026, down 2371.48% year-over-year from $92.2 million in Q2 2025, and down 633.99% quarter-over-quarter from $392.2 million in Q1 2026.
Biogen (BIIB) Net Cash Flow (2009 - 2026) Analysis & Trends
Biogen's Net Cash Flow history runs 18 years deep, the most recent figure standing at -$2.1 billion for Q2 2026.
- In Q2 2026, Net Cash Flow fell 2371.48% year-over-year to -$2.1 billion; the TTM figure through Jun 2026 stood at -$1.5 billion (down 286.28% YoY), while the FY2025 annual figure was $531.6 million, down 61.83% from the prior year.
- Net Cash Flow for Q2 2026 stood at -$2.1 billion, down from $392.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $1.1 billion in Q3 2025, with the low at -$2.1 billion in Q2 2026.
- The 5-year median for Net Cash Flow is -$102.2 million (2024), against an average of -$53.8 million.
- The sharpest annual moves came in 2022 and 2026: Net Cash Flow jumped 718.59% in 2022, then slumped 2371.48% in 2026.
- Biogen's Net Cash Flow stood at -$323.5 million in 2022, then sank by 297.5% to -$1.3 billion in 2023, then soared by 158.34% to $750.2 million in 2024, then tumbled by 214.21% to -$856.8 million in 2025, then slumped by 144.43% to -$2.1 billion in 2026.
- Business Quant data shows BIIB's Net Cash Flow at -$2.1 billion in Q2 2026, $392.2 million in Q1 2026, and -$856.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -2.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.09 Bn |
| Jun 30, 2026 | -2.09 Bn |
| Mar 31, 2026 | 392.20 Mn |
| Mar 31, 2026 | 392.20 Mn |
| Dec 31, 2025 | -856.80 Mn |
| Dec 31, 2025 | -856.80 Mn |
| Sep 30, 2025 | 1.11 Bn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 92.20 Mn |
| Jun 30, 2025 | 92.20 Mn |
| Mar 31, 2025 | 189.00 Mn |
| Mar 31, 2025 | 189.00 Mn |
| Dec 31, 2024 | 750.20 Mn |
| Dec 31, 2024 | 750.20 Mn |
| Sep 30, 2024 | -252.10 Mn |
| Sep 30, 2024 | -252.10 Mn |
| Jun 30, 2024 | 847.10 Mn |
| Jun 30, 2024 | 847.10 Mn |
| Mar 31, 2024 | 47.60 Mn |
| Mar 31, 2024 | 47.60 Mn |